A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Trial Details

NCT ID
NCT05514717
Phase
PHASE1
Sponsor
Mersana Therapeutics
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • XMT-2056
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Stanford, California, United States|37.42411,-122.16608
  • Celebration, Florida, United States|28.32529,-81.53313
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Participant has recurrent or metastatic solid tumors with HER2 expression and has disease progression after treatment, is intolerant to treatment, …
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Participant must have measurable disease as defined by RECIST version 1.1.
  • Participant has fresh tumor biopsy tissue available for submission to central laboratory. If obtaining fresh tumor tissue is medically contraindica…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →